Caris Life Sciences, Inc. (NASDAQ:CAI) Stock Has Average Price Target of $27.82

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $27.82.

CAI has been the topic of a number of recent analyst reports. Evercore reissued an “outperform” rating and set a $26.00 target price on shares of Caris Life Sciences in a report on Thursday, August 6th. BTIG Research upped their price objective on shares of Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings lowered shares of Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. JPMorgan Chase & Co. increased their price objective on shares of Caris Life Sciences from $25.00 to $35.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of Caris Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th.

Insider Activity at Caris Life Sciences

In related news, President David Spetzler sold 478,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total value of $11,883,080.00. Following the transaction, the president owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. This represents a 31.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Russel Denton sold 7,500 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total transaction of $238,650.00. Following the completion of the transaction, the insider directly owned 174,855 shares in the company, valued at approximately $5,563,886.10. This represents a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,004,712 shares of company stock worth $27,205,419. Insiders own 50.00% of the company’s stock.

Hedge Funds Weigh In On Caris Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. IFP Advisors Inc increased its stake in shares of Caris Life Sciences by 143,800.0% during the third quarter. IFP Advisors Inc now owns 4,317 shares of the company’s stock worth $132,000 after purchasing an additional 4,314 shares during the period. Curated Wealth Partners LLC acquired a new stake in Caris Life Sciences during the 3rd quarter worth approximately $261,000. Krilogy Financial LLC acquired a new stake in Caris Life Sciences during the 3rd quarter worth approximately $746,000. NorthCrest Asset Manangement LLC acquired a new stake in Caris Life Sciences during the 3rd quarter worth approximately $529,000. Finally, GAMMA Investing LLC boosted its stake in Caris Life Sciences by 133.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock valued at $39,000 after purchasing an additional 721 shares during the period.

Caris Life Sciences Stock Performance

CAI opened at $30.56 on Friday. Caris Life Sciences has a 12-month low of $14.19 and a 12-month high of $33.13. The stock has a market cap of $8.64 billion, a price-to-earnings ratio of 84.89 and a beta of 0.86. The business has a 50 day moving average of $27.12 and a 200-day moving average of $20.92. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66.

About Caris Life Sciences

Caris Life Sciences is a biotechnology company focused on precision oncology and the use of molecular and artificial intelligence technologies to support cancer diagnosis and treatment decisions. The company analyzes tumor and blood samples to identify genetic, molecular and other biological characteristics that may help physicians select targeted therapies and develop individualized treatment plans.

Its offerings include comprehensive tumor profiling, molecular testing and data-driven clinical support for oncologists and other healthcare providers.